KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects. J of Skin 2025, 9 (6), s712. https://doi.org/10.25251/t4cqj323.